Hackshaw, Allan;
Clarke, Christina A;
Hartman, Anne-Renee;
(2022)
New genomic technologies for multi-cancer early detection: Rethinking the scope of cancer screening.
Cancer Cell
10.1016/j.ccell.2022.01.012.
(In press).
Preview |
Text
Hackshaw_Commentary text - Final.pdf Download (164kB) | Preview |
Abstract
Cancers other than breast, colorectal, cervical, and lung do not have guideline-recommended screening. New multi-cancer early detection (MCED) tests—using a single blood sample—have been developed based on circulating cell-free DNA (cfDNA) or other analytes. In this commentary, we review the current evidence on these tests, provide several major considerations for new MCED tests, and outline how their evaluation will need to differ from that established for traditional single-cancer screening tests.
| Type: | Article |
|---|---|
| Title: | New genomic technologies for multi-cancer early detection: Rethinking the scope of cancer screening |
| Open access status: | An open access version is available from UCL Discovery |
| DOI: | 10.1016/j.ccell.2022.01.012 |
| Publisher version: | https://doi.org/10.1016/j.ccell.2022.01.012 |
| Language: | English |
| Additional information: | This version is the author accepted manuscript. For information on re-use, please refer to the publisher's terms and conditions. |
| UCL classification: | UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences > Faculty of Medical Sciences UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences > Faculty of Medical Sciences > Cancer Institute > CRUK Cancer Trials Centre UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences UCL UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences > Faculty of Medical Sciences > Cancer Institute |
| URI: | https://discovery.ucl.ac.uk/id/eprint/10143164 |
Archive Staff Only
 |
View Item |
